Today: 19 May 2026
Browse Category

NASDAQ:DYN 7 October 2025 - 4 January 2026

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

TuHURA Biosciences plunged 36.9% after announcing a $15.6 million direct offering with warrants, triggering heavy dilution concerns. Phreesia, Euda Health, SLM Corp, Virgin Galactic, and Gogo each fell more than 15%. Major indexes stayed mostly flat, with the Dow up 0.2% and the S&P 500 up 0.1% as traders awaited the Federal Reserve’s policy decision.
9 December 2025
··········
Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics Stock Soars on Duchenne Trial Data: What December 8 Means for DYN Investors

Dyne Therapeutics shares jumped 14% to $23.20 by mid-afternoon Monday after the company reported its Phase 1/2 DELIVER trial in Duchenne muscular dystrophy met its primary endpoint. The stock touched an intraday high near $25.68 on volume over 2.5 million shares. Dyne plans to seek U.S. accelerated approval in 2026. The company reported $792 million in cash as of Q3 2025.
8 December 2025
·
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics shares jumped over 10% to around $14 after new trial data showed its lead therapy improved muscle function with no serious side effects. The stock is up about 75% in six months. Dyne’s Duchenne drug just received Orphan Drug status in Japan and positive analyst upgrades, with price targets averaging $34. The company ended June with $683.9 million in cash, extending its runway into 2027.
7 October 2025
·

Stock Market Today

  • 3 Dividend Stocks Seen as Reliable Investments: ExxonMobil, Johnson & Johnson, Coca-Cola
    May 19, 2026, 2:55 PM EDT. Three blue chip stocks offering steady dividends and long-term growth potential standout amid market uncertainty. ExxonMobil, a giant in energy operations spanning 56 countries, has raised dividends for 43 years and yields 2.6% forward. Analysts project its earnings per share to grow at 19% annually through 2028. Johnson & Johnson, with a 64-year history of dividend increases, yields 2.3%, benefiting from a focused pharmaceutical and medical device portfolio. Coca-Cola also remains a favored choice for reliable income. These firms combine established market positions with dividend reliability, making them attractive to investors seeking stability and growth over multiple years, contrasting with more volatile stock selections or broad index funds.

Latest articles

Marvell Stock Is Jumping Again — The AI Chip Trade Has One Week To Prove It

Marvell Stock Is Jumping Again — The AI Chip Trade Has One Week To Prove It

19 May 2026
Marvell shares climbed 6.6% to $180.04 Tuesday, outperforming a falling Nasdaq as investors positioned ahead of its May 27 earnings call. Trading volume reached 15.3 million shares, with the company’s market value near $155.5 billion. The stock’s rally followed analyst price target hikes and speculation over AI data-center demand. Marvell last reported record annual revenue and forecast further growth led by its data-center business.
Enbridge Stock Hits a 52-Week High Even as Line 5 Fight Throws Up a Fresh Risk

Enbridge Stock Hits a 52-Week High Even as Line 5 Fight Throws Up a Fresh Risk

19 May 2026
Enbridge Inc. shares hit a 52-week high of C$78.25 on Tuesday, rising 2.76% even as the S&P/TSX Composite slipped 0.1% amid inflation concerns. The move came after the company reaffirmed 2026 financial guidance and despite a partial construction pause on its Line 5 project in Wisconsin. Pembina Pipeline shares also rose, though less sharply.
Amazon shares fall as $200 billion AI question lingers

Amazon shares fall as $200 billion AI question lingers

19 May 2026
Amazon shares fell 2.3% to $258.73 Tuesday, underperforming the S&P 500 and Nasdaq as investors trimmed tech holdings ahead of Nvidia’s earnings. AWS revenue jumped 28% to $37.6 billion last quarter, but Amazon’s free cash flow dropped to $1.2 billion over the past year from $25.9 billion, reflecting heavy AI spending.
Go toTop